Spino-Cerebellar Ataxia 3(SCA3) - Machado-Joseph Disease

 Machado-Joseph Disease(MJD) - SCA3

Machado-Joseph disease (MJD)—also called spinocerebellar ataxia Type 3 (SCA3)—is one of approximately 30 recognized, dominantly inherited forms of ataxia.  Ataxia is a general term meaning lack of muscle control or coordination.  MJD is characterized by slowly progressive clumsiness in the arms and legs, a staggering lurching gait that can be mistaken for drunkenness, difficulty with speech and swallowing, impaired eye movements sometimes accompanied by double vision or bulging eyes, and lower limb spasticity.

Ataxia is a rare neurological progressive disease with no cure.

About us

CureSCA, Cure Spino-Cerebellar Ataxia,  is a charity dedicated to help patients and families affected by SpinoCerebellar Ataxia 3.


What we do

Our aim is to work collaboratively with leading Ataxia charities, reasearchers and health professionals to fund research studies that specifically focuses on slowing down the disease progression and improve the quality of life for patients with SCA3.

What is Ataxia?

A comprehensive information on Ataxia can be found below.


More on SCA3/MJD

More information on SCA3 can be found here.



Our goals and objectives

Spread Awareness

Spread Awareness of Ataxia, specifically SCA3



Work with local, national and international charities to help find a cure and to improve quality of lifestyle for patients afflicted with SCA3


Fund Research

Raise funds to award research grants for research projects that focus on slowing the disease progression

Leverage Technology

Set-up an Ataxia open research portal that leverages Artificial Intelligence and Deep Learning technologies to facilitate exchange of research ideas and spur innovation and breakthroughs

Repurposed drugs

Stem Cell Therapy

Gene Therapy

Antisense Therapy





We strongly recommend all patients to register and support following leading charities helping people affected by Ataxia. 




Email: curesca3@outlook.com


This website and its content is made available for you to freely copy and redistribute under the CC BY 4.0 license